Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Francisco Javier Peñalver Párraga, José Antonio Márquez Navarro, Soledad Durán Nieto, Pilar Giraldo Castellano, Carlos Montalbán Sanz, María José Ramírez Sánchez, Juan-Manuel Sancho Cia, María José Terol Castera, Francisco Javier Capote Huelva, Antonio Gutiérrez García, Blanca Sánchez González, Antonio Salar Silvestre, Miguel Canales Albendea, MD PhD, María Dolores Caballero Barrigón

Blood (2016) 128 (22): 1788.

https://doi.org/10.1182/blood.V128.22.1788.1788

Published: 2016

Journal Articles

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Juan-Manuel Sancho, Francisco Gual, Rubén Fernández-Alvarez, Esther González-García, MD, Carlos Grande, MD PhD, Carmen Jiménez-López, Norma C Gutierrez, MD PhD, María-José Peñarrubia, Ana Batlle, Eva González-Barca, MD PhD, Jose-Maria Guinea-de-Castro, Eva Gimeno, MD PhD, Francisco-Javier Peñalver, MD, Miguel A Fuertes, Jorge Gayoso, MD, José-Ángel Hernández-Rivas, José-María Moraleda, MD PhD, Lluis Virgili, Alejandro Martín, MD PhD

Blood (2016) 128 (22): 5387.

https://doi.org/10.1182/blood.V128.22.5387.5387

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Blood (2016) 128 (22): 4201.

https://doi.org/10.1182/blood.V128.22.4201.4201

Published: 2016

Journal Articles

Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Blood (2015) 126 (23): 2962.

https://doi.org/10.1182/blood.V126.23.2962.2962

Published: 2015

Journal Articles

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Blood (2015) 126 (23): 1514.

https://doi.org/10.1182/blood.V126.23.1514.1514

Published: 2015

Journal Articles

Flow Cytometric Detection of Liposomes in the CSF of Patients with NHL/ALL, Treated with Intrathecal Liposomal Cytarabine: Synonymous of Toxicity?

Francisco Javier Peñalver, Martínez-Barranco Pilar, Lucía Villalón, MD, Manuel Barón, L Martín, Pilar Ricard, Karmele Arribalzaga, María José Garcia Bueno, Alberto Orfao, MD PhD

Blood (2014) 124 (21): 5444.

https://doi.org/10.1182/blood.V124.21.5444.5444

Published: 2014

Journal Articles

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Blood (2014) 124 (12): 1887–1893.

https://doi.org/10.1182/blood-2014-05-573733

Published: 2014

Journal Articles

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Blood (2014) 123 (12): 1864–1869.

https://doi.org/10.1182/blood-2013-11-537993

Published: 2014

Includes: Supplemental data

Journal Articles

Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression

Blood (2013) 122 (21): 1973.

https://doi.org/10.1182/blood.V122.21.1973.1973

Published: 2013

Journal Articles

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

Blood (2012) 120 (21): 4599.

https://doi.org/10.1182/blood.V120.21.4599.4599

Published: 2012

Journal Articles

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Antonio Salar, MD, Eva Domingo-Domenech, MD, Carlos Panizo, Concepción Nicolás, MD, Joan Bargay, Ana Muntanola, MD, Miguel Canales, Jose Luis Bello, MD, juan Manuel Sancho, Sr., MD, Jose Francisco Tomas, MD, María José Rodriguez, MD, Francisco-Javier Penalver, Luis Palomera, MD, Carlos Grande, José J Sánchez-Blanco, MD, Reyes Arranz, MD, Eulogio Conde, Dolores Caballero, MD, Carlos Montalban

Blood (2012) 120 (21): 3691.

https://doi.org/10.1182/blood.V120.21.3691.3691

Published: 2012

Journal Articles

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

Blood (2012) 120 (13): 2581–2588.

https://doi.org/10.1182/blood-2012-05-427815

Published: 2012

Includes: Supplemental data

Journal Articles

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

Blood (2011) 118 (17): 4547–4553.

https://doi.org/10.1182/blood-2011-04-345801

Published: 2011

Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood (2010) 116 (21): 2448.

https://doi.org/10.1182/blood.V116.21.2448.2448

Published: 2010

Journal Articles

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Blood (2010) 116 (21): 309.

https://doi.org/10.1182/blood.V116.21.309.309

Published: 2010

NARROW

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Flow Cytometric Detection of Liposomes in the CSF of Patients with NHL/ALL, Treated with Intrathecal Liposomal Cytarabine: Synonymous of Toxicity?

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only